Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile

This article was originally published in The Pink Sheet Daily

Executive Summary

Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx’s Nexavar .

Advertisement

Related Content

Aveo’s Tivozanib Will Face Challenging Survival Data At ODAC Review
Germany’s IQWiG: New Year, Same Sternness On Dossier Structure
Vertex's Cystic Fibrosis Drug Kalydeco Given Green Light By EU's Scientific Advisory Panel
Cancer Imaging In Clear Cell Renal Carcinoma Gets ODAC Attention As Pipeline Fills
Xalkori And The Art Of Modern Drug Development
Business News, In Brief
Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
Pfizer’s Crizotinib Eases Past FDA With Targeted Population

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel